We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Hologic Completes the Acquisition of Gen-Probe

By LabMedica International staff writers
Posted on 06 Aug 2012
Hologic (Bedford, MA, USA) has completed the acquisition of Gen-Probe (San Diego, CA, USA) for a net purchase price of USD 3.72 billion. More...


Gen-Probe is a molecular diagnostics company with services used to diagnose human diseases, screen donated human blood, ensure transplant compatibility, and aid biomedical research.

The acquisition will allow Hologic to expand its growing diagnostics products and services business. Hologic, Inc. is a developer, manufacturer, and supplier of diagnostic products, medical imaging systems, and surgical products. The company operates four core business units focused on breast health, diagnostics, GYN surgical, and skeletal health.

“Gen-Probe is an ideal partner and strategic fit to Hologic’s existing diagnostics business and complements our focus on scaling and diversifying our diagnostics franchise,” Robert A. Cascella, the chief executive of Hologic, said in a statement. “Our combined company will be well positioned globally to capitalize on the fast-growing molecular diagnostics market with an established global infrastructure.”

Related Links:

Hologic
Gen-Probe





New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.